Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis2018-01-17T17:05:05-05:00
When marketing and science intersect: Do patients with MS benefit? When marketing and science intersect: Do patients with MS benefit?2018-01-17T17:01:42-05:00
Effect of relapses on development of residual deficit in multiple sclerosis Effect of relapses on development of residual deficit in multiple sclerosis2018-01-17T17:01:42-05:00
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis2018-01-17T17:00:50-05:00
